Renosart 50 mg (Tablet)
Unit Price: ৳ 8.00 (50's pack: ৳ 400.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Losartan potassium |
| Company | Leon pharmaceuticals ltd |
Indications
- Treatment of hypertension
- Renal protection in type-2 diabetic patients with proteinuria
Pharmacology
- First non-peptide orally active angiotensin II receptor blocker
- Binds to the AT1 receptor in various tissues
- Reduces vasoconstriction and aldosterone release
Dosage & Administration
- Usual starting and maintenance dose of 50 mg once daily
- 25 mg twice daily recommended if 50 mg once daily is inadequate
- Starting dose of 25 mg once daily for patients with intravascular volume-depletion
- Total daily dose ranges from 25 mg to 100 mg
- Lower starting dose of 25 mg once daily recommended for patients over 75 years
Interactions
- Reduction of active metabolite levels with rifampicin and fluconazole
- Potentiation of antihypertensive effects with hydrochlorothiazide
- Increases in serum potassium with potassium-sparing diuretics, potassium supplements, or salt substitutes
- Attenuation of antihypertensive effect by indomethacin
- Increased risk of renal impairment with concomitant use of certain drugs
Contraindications
- Pregnant women
- Patients hypersensitive to any component of the product
- Concomitant use with Aliskiren in patients with diabetes
Side Effects
- Mild and transient side effects
- Common side effects: dizziness, diarrhea, nasal congestion, cough, upper respiratory infection
- Other side effects: fatigue, edema, abdominal pain, chest pain, nausea, headache, pharyngitis
Pregnancy & Lactation
- Pregnancy Category D
- Increased risk to the fetus if administered during second or third trimesters
- Uncertain excretion in human milk
- Consideration for discontinuing nursing or the drug
Precautions & Warnings
- Reduced fetal renal function and increased fetal and neonatal morbidity and death
- Risk of symptomatic hypotension in intravascularly volume-depleted patients
- Significantly increased plasma concentrations in cirrhotic patients
- Reported changes in renal function, including renal failure, in renal impaired patients
Use in Special Populations
- No initial dosage adjustment necessary in patients with mild renal impairment
- Lower starting dose recommended for patients with moderate to severe renal impairment or on dialysis
- Lower dose consideration for patients with a history of hepatic impairment
Therapeutic Class
- Angiotensin II receptor blocker
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children